Search research articles
Contact Us
Filters
Showing results (91-100 of 120) with videos related to
Page
of 12
Sort By:
Journal of Neuro-Oncology
|
June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Andrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Journal of Neuro-Oncology
|
October 9, 2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02
Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, et al.
Neuro-Oncology Advances
|
November 29, 2023
NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma
Tracy T Batchelor, Minhee Won, Arnab Chakravarti, et al.
Journal of Palliative Medicine
|
June 28, 2014
ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases
, Simon Shek-Man Lo, Elizabeth M Gore, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2010
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma
Phioanh Leia Nghiemphu, Patrick Y Wen, Kathleen R Lamborn, et al.
Neuro-Oncology
|
February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
Jeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Neuro-Oncology
|
October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
Neuro-Oncology
|
February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
Timothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Neuro-Oncology Advances
|
November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02
Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 120) with videos related to
Sort By:
Page
of 12
Journal of Neuro-Oncology
|
June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Andrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Journal of Neuro-Oncology
|
October 9, 2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02
Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, et al.
Neuro-Oncology Advances
|
November 29, 2023
NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma
Tracy T Batchelor, Minhee Won, Arnab Chakravarti, et al.
Journal of Palliative Medicine
|
June 28, 2014
ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases
, Simon Shek-Man Lo, Elizabeth M Gore, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2010
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma
Phioanh Leia Nghiemphu, Patrick Y Wen, Kathleen R Lamborn, et al.
Neuro-Oncology
|
February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
Jeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Neuro-Oncology
|
October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
Neuro-Oncology
|
February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
Timothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Neuro-Oncology Advances
|
November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02
Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Page
of 12